AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22032743 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral cathodal superior temporal gyrus (STG) stimulation (n = 5)
Number of subjects: 12
Study 22032743 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 12
Study 18164304 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin
Number of subjects: 600
Study 18164304 — intervention group
Group type: COMPARATOR
Intervention: Ergometrine
Number of subjects: 600
Study 16582128 — intervention group
Group type: EXPERIMENTAL
Intervention: l-arginine
Number of subjects: 45
Study 16582128 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 14514973 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 175 mg/m2 and carboplatin AUC = 6 with amifostine 910 mg/m2 (group B)
Number of subjects: 38
Study 14514973 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (group A)
Number of subjects: 38
Study 10730613 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical cardioversion (protocol: 200, 300, 360 J)
Number of subjects: 19
Study 10730613 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological cardioversion (quinidine)
Number of subjects: 19
Study 10730613 — intervention group
Group type: COMPARATOR
Intervention: Electrical cardioversion
Number of subjects: 19
Study 10730613 — intervention group
Group type: COMPARATOR
Intervention: Pharmacological cardioversion
Number of subjects: 19
Study 8956954 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextran 70
Number of subjects: 40
Study 8956954 — intervention group
Group type: COMPARATOR
Intervention: Albumin
Number of subjects: 40
Study 1316074 — intervention group
Group type: EXPERIMENTAL
Intervention: Lomefloxacin (400 mg orally once daily for 7-10 days)
Number of subjects: 254
Study 1316074 — intervention group
Group type: COMPARATOR
Intervention: TMP/SMX (160 mg/800 mg orally twice daily for 7-10 days)
Number of subjects: 254
Study 2860441 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight reduction
Number of subjects: 56
Study 2860441 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (200 mg daily)
Number of subjects: 56
Study 2860441 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 29193881 — intervention group
Group type: COMPARATOR
Intervention: Knowledge of Disease Management‐Cystic Fibrosis measure (KDM‐CF‐P)
Number of subjects: 196
Study 29193881 — intervention group
Group type: COMPARATOR
Intervention: KDM‐CF‐P (19 items)
Number of subjects: 196
Study 29193881 — intervention group
Group type: COMPARATOR
Intervention: KDM‐CF‐P
Number of subjects: 196
Study 26045250 — intervention group
Group type: EXPERIMENTAL
Intervention: Denicotinized cigarettes (DNCs) used ad libitum over 2 weeks in addition to standard treatment (ST)
Number of subjects: 200
Study 26045250 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (ST) alone
Number of subjects: 200
Study 24531244 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 52
Study 24531244 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 52
Study 21967300 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer games operated by leaning in a seated position, duration: 3 months, controlled using a sitting platform that detects pressure changes.
Number of subjects: 0
Study 21967300 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group), duration: 3 months, participants acted as their own controls.
Number of subjects: 0
Study 20925607 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified definition of fetal heart rate deceleration
Number of subjects: 104
Study 20925607 — intervention group
Group type: COMPARATOR
Intervention: Standard definition of fetal heart rate deceleration
Number of subjects: 104
Study 18541548 — intervention group
Group type: EXPERIMENTAL
Intervention: n‐3 FAs group (1.7 g DHA and 0.6 g EPA)
Number of subjects: 174
Study 18541548 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 174
Study 16758479 — intervention group
Group type: EXPERIMENTAL
Intervention: Riluzole (200 mg/day)
Number of subjects: 15
Study 16758479 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 15
Study 12680887 — intervention group
Group type: COMPARATOR
Intervention: Quazepam 20 mg after fasting overnight
Number of subjects: 9
Study 12680887 — intervention group
Group type: EXPERIMENTAL
Intervention: Quazepam 20 mg 30 min after eating a standard meal
Number of subjects: 9
Study 12680887 — intervention group
Group type: EXPERIMENTAL
Intervention: Quazepam 20 mg 3 h after eating a standard meal
Number of subjects: 9
Study 9004103 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (nitrendipine 10-40 mg/day, captopril 12.5-50 mg/day, hydrochlorothiazide 12.5-50 mg/day as necessary)
Number of subjects: 1245
Study 9004103 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1245
Study 1310374 — intervention group
Group type: EXPERIMENTAL
Intervention: High-linoleic acid (LA) diet
Number of subjects: 30
Study 1310374 — intervention group
Group type: COMPARATOR
Intervention: Low-linoleic acid (LA) diet
Number of subjects: 30
Study 1310374 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish-oil supplement (1.6 g EPA/d and 0.32 g DHA as triglycerides)
Number of subjects: 30
Study 1310374 — intervention group
Group type: COMPARATOR
Intervention: Control (no fish-oil supplement)
Number of subjects: 30
Study 6395815 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinidazole 600 mg twice daily for five days
Number of subjects: 0
Study 6395815 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole 800 mg three times daily for five days
Number of subjects: 0
Study 30204729 — intervention group
Group type: EXPERIMENTAL
Intervention: Facedown (FD) positioning for 3 days after surgery
Number of subjects: 80
Study 30204729 — intervention group
Group type: COMPARATOR
Intervention: No-facedown (nFD) positioning
Number of subjects: 80
Study 30551340 — intervention group
Group type: EXPERIMENTAL
Intervention: SCIT + TAU
Number of subjects: 30
Study 30551340 — intervention group
Group type: COMPARATOR
Intervention: TAU
Number of subjects: 30
Study 26508531 — intervention group
Group type: EXPERIMENTAL
Intervention: FIFA 11+ Kids intervention (15-min warm-up programme, twice a week for 10 weeks)
Number of subjects: 123
Study 26508531 — intervention group
Group type: EXPERIMENTAL
Intervention: FIFA 11+ Kids intervention
Number of subjects: 123
Study 26508531 — intervention group
Group type: COMPARATOR
Intervention: Standard warm-up (sham treatment)
Number of subjects: 123
Study 24581993 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive Simulation
Number of subjects: 56
Study 24581993 — intervention group
Group type: EXPERIMENTAL
Intervention: Non‐interactive Simulation
Number of subjects: 56
Study 24581993 — intervention group
Group type: EXPERIMENTAL
Intervention: Video Tutorial
Number of subjects: 56
Study 24581993 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 56
Study 22924354 — intervention group
Group type: EXPERIMENTAL
Intervention: Acacia arabica gel
Number of subjects: 120
Study 22924354 — intervention group
Group type: EXPERIMENTAL
Intervention: Acacia arabica powder
Number of subjects: 120
Study 22924354 — intervention group
Group type: COMPARATOR
Intervention: 1% chlorhexidine gel
Number of subjects: 120
Study 22924354 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 20731975 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based training version of cognitive-behavioral therapy
Number of subjects: 76
Study 17591660 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketamine
Number of subjects: 0
Study 17591660 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17591660 — intervention group
Group type: COMPARATOR
Intervention: Schizophrenia
Number of subjects: 0
Study 17591660 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study 16249780 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesitherapy (KT) and orthoses (O) (O+KT group)
Number of subjects: 48
Study 16249780 — intervention group
Group type: COMPARATOR
Intervention: Orthoses (O) group
Number of subjects: 48
Study 11927475 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil infusion at a rate of 0.1 microg x kg(‐1) x min(‐1) for 20 min
Number of subjects: 13
Study 11927475 — intervention group
Group type: COMPARATOR
Intervention: Control group with normal renal function
Number of subjects: 13
Study 11927475 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil infusion in renal failure group
Number of subjects: 13
Study 11927475 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil infusion in control group
Number of subjects: 13
Study 10188118 — intervention group
Group type: EXPERIMENTAL
Intervention: Unna cap dressing (Aquaphor gauze and Dome Paste gauze, wound care every 3 days)
Number of subjects: 12
Study 10188118 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (Xeroform gauze, daily wound care)
Number of subjects: 12
Study 8654454 — intervention group
Group type: EXPERIMENTAL
Intervention: MR imaging
Number of subjects: 21
Study 8654454 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrumented valgus‐varus laxity tester (VVLT)
Number of subjects: 21
Study 2138048 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin
Number of subjects: 22
Study 7004050 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral PGE2 (0.5 mg initial dose, followed by 1.0 mg at hourly intervals for up to 24 hours)
Number of subjects: 200
Study 7004050 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of oxytocin (dose increased stepwise up to 20 mIU/min)
Number of subjects: 200
Study 7004050 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral PGE2 or intravenous infusion of oxytocin combined with early amniotomy
Number of subjects: 200
Study 7004050 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin alone
Number of subjects: 200
Study 7004050 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral PGE2 or intravenous infusion of oxytocin
Number of subjects: 200
Study 30388320 — intervention group
Group type: EXPERIMENTAL
Intervention: Triptorelin 22.5 mg/24 week depot injections
Number of subjects: 58
Study 30388320 — intervention group
Group type: COMPARATOR
Intervention: Subcapsular orchiectomy
Number of subjects: 58
Study 30388320 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT)
Number of subjects: 58
Study 28394850 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet Group (n = 84)
Number of subjects: 178
Study 28394850 — intervention group
Group type: COMPARATOR
Intervention: Workbook Group (n = 94)
Number of subjects: 178
Study 25586473 — intervention group
Group type: EXPERIMENTAL
Intervention: Avatar-based online self-management program
Number of subjects: 41
Study 25586473 — intervention group
Group type: COMPARATOR
Intervention: Control group (identical online program with voice only)
Number of subjects: 41
Study 23811316 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week arm-cranking exercise program (3 sessions/week, moderate intensity 50%-65% HRR)
Number of subjects: 17
Study 23811316 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week arm-cranking exercise program
Number of subjects: 17
Study 21232631 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 group (6 g/day of fish oil for ≥1 month)
Number of subjects: 49
Study 19133920 — intervention group
Group type: EXPERIMENTAL
Intervention: Desloratadine (DL) 5 mg/day (continuous)
Number of subjects: 106
Study 19133920 — intervention group
Group type: COMPARATOR
Intervention: Desloratadine (DL) PRN
Number of subjects: 106
Study 17340895 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium oxide (TiO) implants
Number of subjects: 10
Study 17340895 — intervention group
Group type: COMPARATOR
Intervention: Machined implants
Number of subjects: 10
Study 17340895 — intervention group
Group type: COMPARATOR
Intervention: Both TiO and machined implants
Number of subjects: 10
Study 17340895 — intervention group
Group type: COMPARATOR
Intervention: Machined implants in distal positions
Number of subjects: 10
Study 15452389 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower limb compression bandaging (pressure approximately 30 mm Hg)
Number of subjects: 61
Study 15452389 — intervention group
Group type: COMPARATOR
Intervention: Unbandaged state
Number of subjects: 61
Study 15452389 — intervention group
Group type: EXPERIMENTAL
Intervention: Bandaged state
Number of subjects: 61
Study 11258688 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialty clinic asthma care (intensive medical and environmental control, education, close monitoring, 24-hour availability)
Number of subjects: 300
Study 11258688 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialty clinic asthma care
Number of subjects: 300
Study 9926148 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (6‐min treadmill walking test and five walking sessions per day at > or = 75% of the respective treadmill walking distance)
Number of subjects: 29
Study 9926148 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 29
Study 9926148 — intervention group
Group type: COMPARATOR
Intervention: Control group (only treadmill walking tests on days 1, 5, and 10)
Number of subjects: 29
Study 8056732 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine (DMI) 200 mg daily in divided doses
Number of subjects: 60
Study 8056732 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 8056732 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine (DMI)
Number of subjects: 60
Study 2737733 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilevalol 200-400 mg daily
Number of subjects: 12
Study 2737733 — intervention group
Group type: COMPARATOR
Intervention: Atenolol 50-100 mg daily
Number of subjects: 12
Study 31398669 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine salicylate (0.04 mg/kg initial dose, followed by continuous infusion of 1 mg/h for up to 120 h)
Number of subjects: 20
Study 31398669 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% sodium chloride)
Number of subjects: 20
Study 28441944 — intervention group
Group type: EXPERIMENTAL
Intervention: Cash transfer program (CTP) of US$40 monthly for 6 months
Number of subjects: 0
Study 28441944 — intervention group
Group type: COMPARATOR
Intervention: Control group (no cash transfer)
Number of subjects: 0
Study 26493793 — intervention group
Group type: EXPERIMENTAL
Intervention: carlumab 1 mg·kg(‐1)
Number of subjects: 126
Study 26493793 — intervention group
Group type: EXPERIMENTAL
Intervention: carlumab 5 mg·kg(‐1)
Number of subjects: 126
Study 26493793 — intervention group
Group type: EXPERIMENTAL
Intervention: carlumab 15 mg·kg(‐1)
Number of subjects: 126
Study 26493793 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 126
Study 24298731 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban (60 mg once daily) after initial heparin (5 days)
Number of subjects: 0
Study 24298731 — intervention group
Group type: COMPARATOR
Intervention: Warfarin (INR of 2.0-3.0) after initial heparin (5 days)
Number of subjects: 0
Study 24298731 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban (30 mg once daily)
Number of subjects: 0
Study 21486803 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion of N(G)-nitro-L-arginine methyl ester (L-NAME) for 5 min to inhibit NOS during continuous SS hypoxia
Number of subjects: 20
Study 21486803 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion of ketorolac for 5 min to inhibit COX during continuous SS hypoxia
Number of subjects: 20
Study 21486803 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined NOS and COX inhibition
Number of subjects: 20
Study 21486803 — intervention group
Group type: COMPARATOR
Intervention: Infusion of ketorolac during SS hypoxia
Number of subjects: 20
Study 21486803 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion of L-NAME during continuous SS hypoxia
Number of subjects: 20
Study 19321206 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone augmentation
Number of subjects: 0
Study 19321206 — intervention group
Group type: COMPARATOR
Intervention: Placebo augmentation
Number of subjects: 0
Study 19321206 — intervention group
Group type: EXPERIMENTAL
Intervention: PaRTS‐D instrument
Number of subjects: 0
Study 19321206 — intervention group
Group type: EXPERIMENTAL
Intervention: PaRTS‐D scores
Number of subjects: 0
Study 16677167 — intervention group
Group type: EXPERIMENTAL
Intervention: Camostat mesilate 200 mg three times daily
Number of subjects: 0
Study 16677167 — intervention group
Group type: COMPARATOR
Intervention: Famotidine 20 mg twice daily
Number of subjects: 0
Study 14997744 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammographic screening for breast cancer
Number of subjects: 0
Study 11174691 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle mortise separation adjustment
Number of subjects: 30
Study 11174691 — intervention group
Group type: COMPARATOR
Intervention: Detuned ultrasound treatment (placebo)
Number of subjects: 30
Study 9413706 — intervention group
Group type: EXPERIMENTAL
Intervention: Metrifonate (loading/maintenance dosages 2/0.65 mg/kg/day for 2 and 10 weeks)
Number of subjects: 119
Study 9413706 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 120)
Number of subjects: 119
Study 8423964 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational brochure
Number of subjects: 125
Study 8423964 — intervention group
Group type: COMPARATOR
Intervention: No brochure (Control)
Number of subjects: 125
Study 3680568 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciramadol 30 mg
Number of subjects: 43
Study 3680568 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciramadol 90 mg
Number of subjects: 43
Study 3680568 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine 60 mg
Number of subjects: 43
Study 3680568 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 28834135 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 1000 mg twice daily
Number of subjects: 40
Study 26762910 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphilimus-eluting stents (AES)
Number of subjects: 112
Study 26762910 — intervention group
Group type: COMPARATOR
Intervention: Everolimus-eluting stents (EES)
Number of subjects: 112
Study 24760401 — intervention group
Group type: EXPERIMENTAL
Intervention: Icosapent ethyl (IPE) 4 g/day co-administered with warfarin 25 mg
Number of subjects: 25
Study 24760401 — intervention group
Group type: COMPARATOR
Intervention: Warfarin 25 mg without IPE
Number of subjects: 25
Study 22087805 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpaste containing aloe vera
Number of subjects: 90
Study 22087805 — intervention group
Group type: COMPARATOR
Intervention: Placebo toothpaste
Number of subjects: 90
Study 22087805 — intervention group
Group type: COMPARATOR
Intervention: Toothpaste with polymer and fluoride containing triclosan
Number of subjects: 90
Study 20334770 — intervention group
Group type: EXPERIMENTAL
Intervention: n-of-1 trials
Number of subjects: 0
Study 18942671 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased co-payments for PBS medicines (24% increase in January 2005)
Number of subjects: 17
Study 18942671 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased co-payments for PBS medicines
Number of subjects: 17
Study 15966872 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic scaler (US group)
Number of subjects: 12
Study 15966872 — intervention group
Group type: COMPARATOR
Intervention: Gracey curettes (CC group)
Number of subjects: 12
Study 11878061 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of enalapril and losartan
Number of subjects: 186
Study 11878061 — intervention group
Group type: COMPARATOR
Intervention: Enalapril alone
Number of subjects: 186
Study 11878061 — intervention group
Group type: COMPARATOR
Intervention: Losartan alone
Number of subjects: 186
Study 11878061 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 186
Study 11055597 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftibuten (once daily for 5 days)
Number of subjects: 248
Study 11055597 — intervention group
Group type: COMPARATOR
Intervention: Azithromycin (for 3 days)
Number of subjects: 248
Study 11055597 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftibuten
Number of subjects: 248
Study 11055597 — intervention group
Group type: COMPARATOR
Intervention: Azithromycin
Number of subjects: 248
Study 9346386 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV genotype 1b
Number of subjects: 101
Study 9346386 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV genotype 2a
Number of subjects: 101
Study 9346386 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV genotyping by RT‐PCR
Number of subjects: 101
Study 9346386 — intervention group
Group type: EXPERIMENTAL
Intervention: Type-specific antibodies detection
Number of subjects: 101
Study 8455312 — intervention group
Group type: EXPERIMENTAL
Intervention: Casein-based enteral nutrition product (1000 kcal, 34 g of proteins)
Number of subjects: 51
Study 8455312 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsule
Number of subjects: 51
Study 3954936 — intervention group
Group type: EXPERIMENTAL
Intervention: Brotizolam with ethanol (0.25 mg dose)
Number of subjects: 13
Study 3954936 — intervention group
Group type: COMPARATOR
Intervention: Brotizolam with placebo
Number of subjects: 13
Study 3954936 — intervention group
Group type: EXPERIMENTAL
Intervention: Brotizolam with ethanol
Number of subjects: 13
Study 28922787 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole for 2.5 years
Number of subjects: 1824
Study 28922787 — intervention group
Group type: COMPARATOR
Intervention: Letrozole for 5 years
Number of subjects: 1824
Study 27378679 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting posture during rounds
Number of subjects: 0
Study 27378679 — intervention group
Group type: COMPARATOR
Intervention: Standing posture during rounds
Number of subjects: 0
Study 24219394 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to misleading information
Number of subjects: 0
Study 24219394 — intervention group
Group type: EXPERIMENTAL
Intervention: Arousal
Number of subjects: 0
Study 24219394 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative valence and arousal
Number of subjects: 0
Study 24219394 — intervention group
Group type: COMPARATOR
Intervention: Previous exposure to misinformation
Number of subjects: 0
Study 22164329 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing Awareness Meditation (BAM)
Number of subjects: 162